{ "schemaVersion": 1, "matrixId": "MED-PRE", "matrixVersion": "1.1", "title": "Record Not Rumor — Pre-Event Medication Matrix", "recordCollection": "The Clancy Records", "validatedSourceState": "MED-PRE-v1.1-VALIDATED", "validatedDate": "2026-08-27", "publicationStatus": "sealed", "scope": "Pre-event psychiatric medication evidence from September 2022 through January 24, 2023, with historical medication information retained only where necessary to distinguish earlier treatment from the active pre-event course. Post-event treatment is excluded from MED-PRE and may not be backfilled into pre-event exposure.", "auditQuestion": "What does the available evidentiary record actually establish about Lindsay Clancy’s psychiatric medication prescribing, availability, reported use, supported exposure, dose, adherence, efficacy, adverse-effect reporting, provider response, objective evidence, and unresolved gaps before January 24, 2023?", "coreRule": "Prescribed ≠ dispensed ≠ possessed ≠ taken ≠ taken as directed ≠ therapeutically exposed ≠ caused a symptom.", "nonScope": [ "This audit does not decide diagnosis.", "This audit does not decide criminal responsibility or lack of criminal responsibility.", "This audit does not decide malpractice.", "This audit does not decide whether medication caused the homicides.", "A subjective report is not treated as proven merely because the report occurred." ], "exposureGradeDefinitions": { "E1": "Strongly bounded exposure.", "E2": "Meaningful supported exposure.", "E3": "Brief or limited exposure.", "E4": "Prescribed or available; meaningful exposure uncertain.", "E0": "Exposure not established." }, "evidenceLabelDefinitions": { "SUPPORTED": "The record establishes the proposition.", "REPORTED": "Attributed statement or report.", "OBSERVED": "Direct provider or collateral observation.", "OBJECTIVE CONSTRAINT": "Pill count, toxicology, physical artifact, or comparable evidence.", "UNRESOLVED": "Available evidence does not answer the question.", "EXCLUDED": "Not relied upon for the pre-event conclusion." }, "entries": [ { "slug": "sertraline-zoloft", "medication": "Sertraline / Zoloft", "exposureState": "Brief supported trial", "exposureGrade": "E3", "effectEfficacyProvenance": "Adverse effects / worsened sleep principally Lindsay self-report", "objectiveAnchor": "Prescription + short-course evidence", "providerConclusionResponse": "Tufts remembered reported effects as non-concerning", "conflictTension": "Causal severity not independently established", "openGap": "Exact dose-by-dose ingestion", "frozenNote": "Do not state Zoloft objectively caused insomnia", "publicationClassification": "Brief supported trial", "keyCanonicalEvidenceIds": ["EV-MED-0018", "EV-MED-0019", "EV-MED-0020", "EV-MED-0063", "EV-MED-0064"], "primarySourceIds": ["SRC-TR-D10"], "representativePinpoints": ["~46:15–46:46", "~56:58–57:30", "~03:19:34–03:19:56"], "readerNote": "Prescription/start/dose plan is distinct from patient-reported adverse effects and medication-specific causation." }, { "slug": "fluoxetine-prozac", "medication": "Fluoxetine / Prozac", "exposureState": "Brief 2022 exposure", "exposureGrade": "E3", "effectEfficacyProvenance": "Worsened sleep = Lindsay report; earlier exposure reportedly helpful/no side effects", "objectiveAnchor": "Prescription/exposure history", "providerConclusionResponse": "Stopped after reported poor tolerance", "conflictTension": "Different exposure episodes prevent universal causation claim", "openGap": "GAP-MED-003", "frozenNote": "Exact 2022 count/duration unresolved", "publicationClassification": "Brief 2022 exposure; separate historical positive report", "keyCanonicalEvidenceIds": ["EV-MED-0065", "EV-MED-0066"], "primarySourceIds": ["SRC-TR-D10", "SRC-TR-D9"], "representativePinpoints": ["D10 ~03:18:00–03:18:44", "D9 ~04:07:54", "D9 ~04:11:19–04:13:11"], "readerNote": "Historical nursing-school experience and 2022 postpartum trial are separate exposure epochs." }, { "slug": "mirtazapine-remeron", "medication": "Mirtazapine / Remeron", "exposureState": "Supported under differing combinations", "exposureGrade": "E2/E3 context-dependent", "effectEfficacyProvenance": "Sleep benefit, disconnection, limited efficacy are combination-specific Lindsay reports", "objectiveAnchor": "Prescription history + contemporaneous communications", "providerConclusionResponse": "Paul treated causation as possible, not certain", "conflictTension": "Do not attribute combination effects to Remeron alone", "openGap": "None material beyond combination chronology", "frozenNote": "Separate Remeron+Klonopin from Remeron+CBD and reportedly untaken combinations", "publicationClassification": "Supported under differing combinations", "keyCanonicalEvidenceIds": ["EV-MED-0013", "EV-MED-0015", "EV-MED-0017", "EV-MED-0062"], "primarySourceIds": ["SRC-TR-D10", "SRC-TR-D9"], "representativePinpoints": ["D10 ~04:33:38–04:34:33", "D10 ~04:36:46–04:36:56", "D9 ~04:11:19–04:12:09"], "readerNote": "Combination-specific reports cannot be assigned to Remeron alone." }, { "slug": "clonazepam-klonopin", "medication": "Clonazepam / Klonopin", "exposureState": "Very brief", "exposureGrade": "E3", "effectEfficacyProvenance": "Disconnection during combination = self-report", "objectiveAnchor": "Two-night contemporaneous report; authoritative Klonopin pill inventory not reproduced", "providerConclusionResponse": "Paul saw no issue stopping after two days", "conflictTension": "Later broad dependence narrative must respect exposure boundary", "openGap": "VAL-MED-007 — authoritative Klonopin pill count unresolved", "frozenNote": "Reported exposure very brief; do not use derivative 11.5/14 until authoritative source is reproduced", "publicationClassification": "Very brief reported exposure", "keyCanonicalEvidenceIds": ["EV-MED-0013", "EV-MED-0014", "EV-MED-0015", "EV-MED-0016", "EV-MED-0062"], "primarySourceIds": ["SRC-TR-D10", "SRC-TR-D9"], "representativePinpoints": ["D10 ~04:33:38–04:34:40", "D9 ~04:11:19–04:12:09"], "readerNote": "Two-night contemporaneous report controls. The unverified 14/11.5 pill count is excluded." }, { "slug": "quetiapine-seroquel", "medication": "Quetiapine / Seroquel", "exposureState": "Meaningful supported exposure", "exposureGrade": "E2", "effectEfficacyProvenance": "Sleep benefit + later depression/spacey/hangover/conversation/HR concerns; most adverse effects self-report", "objectiveAnchor": "Provider-recognized sleep improvement; titration/report mismatch", "providerConclusionResponse": "Jolotta treated sleep/manic-type symptoms; later taper at McLean", "conflictTension": "Simple Seroquel-caused-depression claim in tension with longitudinal chronology", "openGap": "GAP-MED-005; GAP-MED-006", "frozenNote": "Do not equate planned 400 mg with established actual dose", "publicationClassification": "Meaningful supported exposure; 400 mg actual use not established", "keyCanonicalEvidenceIds": ["EV-MED-0004", "EV-MED-0005", "EV-MED-0006", "EV-MED-0046–0052", "EV-MED-0073"], "primarySourceIds": ["SRC-TR-D11", "SRC-TR-D10", "SRC-TR-D20", "SRC-TR-D13", "SRC-TR-D21-WHISPER"], "representativePinpoints": ["D11 ~02:13:59", "D11 ~02:26:10–02:26:25", "D20 ~03:41:25–03:41:46", "D21 ~44:48–47:16"], "readerNote": "Treatment-plan ceiling, reported dose, benefit, adverse reports, and later search artifact remain separate propositions." }, { "slug": "lorazepam-ativan", "medication": "Lorazepam / Ativan", "exposureState": "Supported intermittent/PRN exposure", "exposureGrade": "E2", "effectEfficacyProvenance": "Rebound anxiety/dependence concerns = Lindsay reports", "objectiveAnchor": "Prescription history + lorazepam in toxicology", "providerConclusionResponse": "Provider used longer-acting/taper strategy", "conflictTension": "Withdrawal/dependence not established by patient language", "openGap": "GAP-MED-002", "frozenNote": "Toxicology attribution limited by exact MAR/specimen timing", "publicationClassification": "Supported intermittent/PRN exposure", "keyCanonicalEvidenceIds": ["EV-MED-0011", "EV-MED-0023", "EV-MED-0024", "EV-MED-0053–0057"], "primarySourceIds": ["SRC-TR-D11", "SRC-TR-D7", "SRC-TR-D9"], "representativePinpoints": ["D11 ~52:01–52:05", "D7 ~32:55–33:29", "D7 ~54:46–55:35", "D9 ~03:55:43–03:55:59"], "readerNote": "Toxicology anchors exposure; rebound/dependence language remains patient-originating and timing-limited." }, { "slug": "diazepam-valium", "medication": "Diazepam / Valium", "exposureState": "Meaningful taper exposure", "exposureGrade": "E2", "effectEfficacyProvenance": "Feeling dependent/panic/slower taper requests = Lindsay reports", "objectiveAnchor": "Pill counts + diazepam/metabolites in toxicology + CIWA", "providerConclusionResponse": "Jolotta continued taper; interpreted concern as anxiety about dependence", "conflictTension": "CIWA 1 = minimal-to-no withdrawal at tested encounter", "openGap": "GAP-MED-001; GAP-MED-002", "frozenNote": "Taper does not itself establish addiction/withdrawal", "publicationClassification": "Meaningful taper exposure", "keyCanonicalEvidenceIds": ["EV-MED-0008–0010", "EV-MED-0023", "EV-MED-0024", "EV-MED-0041", "EV-MED-0042", "EV-MED-0057–0061"], "primarySourceIds": ["SRC-TR-D11", "SRC-TR-D7", "SRC-TR-D12"], "representativePinpoints": ["D11 ~02:02:35–02:04:38", "D11 ~02:16:46–02:20:00", "D12 ~17:28–17:59"], "readerNote": "Pill counts and toxicology constrain exposure; CIWA score 1 is encounter-specific." }, { "slug": "trazodone", "medication": "Trazodone", "exposureState": "Supported availability/use", "exposureGrade": "E2", "effectEfficacyProvenance": "Limited efficacy principally self-report", "objectiveAnchor": "Jan. bottle count 30 dispensed / 20 remaining", "providerConclusionResponse": "Adjusted for continuing reported sleep difficulty", "conflictTension": "No objective trazodone-specific sleep failure located", "openGap": "Exact nightly ingestion", "frozenNote": "10 absent tablets do not prove timing or ingestion identity", "publicationClassification": "Supported availability/use", "keyCanonicalEvidenceIds": ["EV-MED-0034–0037"], "primarySourceIds": ["SRC-TR-D10", "SRC-TR-D12"], "representativePinpoints": ["D10 ~04:06:10–04:06:27", "D10 ~02:54:00–02:55:37", "D12 ~16:45–17:22"], "readerNote": "Reported partial sleep benefit and 30/20 bottle count are separate evidence types." }, { "slug": "amitriptyline", "medication": "Amitriptyline", "exposureState": "Strongly bounded 10 mg schedule through Jan. 23", "exposureGrade": "E1", "effectEfficacyProvenance": "No major adverse-effect proposition required", "objectiveAnchor": "30 dispensed / 22 remaining = 8 absent", "providerConclusionResponse": "20 mg increase authorized Jan. 23", "conflictTension": "Physical count does not support extra tablet for 20 mg before event", "openGap": "None material", "frozenNote": "Authorized dose increase ≠ supported higher-dose exposure", "publicationClassification": "Strongly bounded 10 mg schedule; 20 mg authorized but not supported as taken pre-event", "keyCanonicalEvidenceIds": ["EV-MED-0001–0003"], "primarySourceIds": ["SRC-TR-D10"], "representativePinpoints": ["~02:55:41", "~03:39:01–03:40:24"], "readerNote": "Authorization to increase dose is not evidence that the higher dose was ingested." }, { "slug": "lamotrigine-lamictal", "medication": "Lamotrigine / Lamictal", "exposureState": "Prescribed/ordered; actual pre-event ingestion not established. Day 21 provisional testimony indicates filled but not taken; final classification does not rely on that negation pending Rev/audio.", "exposureGrade": "E4/E0 boundary", "effectEfficacyProvenance": "No patient-specific Lamictal adverse effect established; rash discussion is general risk counseling, not an experienced reaction.", "objectiveAnchor": "Order/prescription history; Day 21 fill/non-use testimony remains retrospective and provisional.", "providerConclusionResponse": "25 mg starting plan with slow titration discussed; actual progression not supported.", "conflictTension": "Do not convert prescription, fill, or titration discussion into ingestion.", "openGap": "GAP-MED-009 — final Rev/audio check of Day 21 fill/non-use wording.", "frozenNote": "PUBLICATION-SAFE CORE STATE: prescribed/ordered; actual pre-event ingestion not established. Provisional Day 21 non-use may be footnoted but is not required for the classification.", "publicationClassification": "Prescribed/ordered; actual pre-event ingestion not established", "keyCanonicalEvidenceIds": ["EV-MED-0038–0040", "EV-MED-0071", "EV-MED-0072"], "primarySourceIds": ["SRC-TR-D10", "SRC-TR-D11", "SRC-TR-D21-WHISPER"], "representativePinpoints": ["D10 ~02:46:07–02:46:12", "D11 ~02:47:12–02:49:49", "D21 ~02:11:58–02:13:00"], "readerNote": "Day 21 non-use wording remains provisional in the sealed v1.1 source state; core classification does not depend on it. A Rev Day 21 working transcript became available on August 27 and is recorded in the Source Map as a higher-authority working source for later reconciliation." }, { "slug": "buspirone-buspar", "medication": "Buspirone / BuSpar", "exposureState": "Prescribed; limited sustained exposure evidence for some fills", "exposureGrade": "E4", "effectEfficacyProvenance": "Efficacy/adverse-effect chronology incomplete", "objectiveAnchor": "Near-full / minimally depleted bottle evidence", "providerConclusionResponse": "Chosen as comparatively mild anxiety treatment", "conflictTension": "Prescription history cannot establish sustained use", "openGap": "GAP-MED-004", "frozenNote": "Do not count equally with meaningful exposure drugs", "publicationClassification": "Prescribed; very limited depletion from one documented fill", "keyCanonicalEvidenceIds": ["EV-MED-0030", "EV-MED-0031"], "primarySourceIds": ["SRC-TR-D9", "SRC-TR-OPEN"], "representativePinpoints": ["D9 ~03:57:38–03:59:09", "mixed source later testimony ~02:57:04–02:57:28"], "readerNote": "EV-MED-0031 uses later Patrick Clancy testimony in the mixed Opening Statements file, not opening argument." }, { "slug": "hydroxyzine", "medication": "Hydroxyzine", "exposureState": "PRN; limited exposure", "exposureGrade": "E3/E4", "effectEfficacyProvenance": "No independently observed adverse reaction located", "objectiveAnchor": "27/30 remaining", "providerConclusionResponse": "Offered as non-benzodiazepine option", "conflictTension": "Sustained use unsupported", "openGap": "GAP-MED-004", "frozenNote": "3 absent tablets do not prove 3 ingestions", "publicationClassification": "PRN; limited depletion", "keyCanonicalEvidenceIds": ["EV-MED-0032", "EV-MED-0033"], "primarySourceIds": ["SRC-TR-D9", "SRC-TR-OPEN"], "representativePinpoints": ["D9 ~03:59:11–04:00:52", "mixed source later testimony ~02:57:28–02:58:05"], "readerNote": "Three absent tablets do not prove three ingestions; source segment is later witness testimony, not opening argument." }, { "slug": "diphenhydramine-benadryl", "medication": "Diphenhydramine / Benadryl", "exposureState": "OTC reported exposure", "exposureGrade": "E4", "effectEfficacyProvenance": "Reported helpful with Ativan", "objectiveAnchor": "Historical regimen evidence", "providerConclusionResponse": "Later stopped during regimen change", "conflictTension": "No objective sleep-effect measurement located", "openGap": "Exact dosing", "frozenNote": "Not a separate psychiatric prescription", "publicationClassification": "OTC reported exposure", "keyCanonicalEvidenceIds": ["EV-MED-0054", "EV-MED-0058", "EV-MED-0066"], "primarySourceIds": ["SRC-TR-D9", "SRC-TR-D11"], "representativePinpoints": ["D9 ~04:11:18–04:13:11", "D11 ~02:08:41–02:10:10"], "readerNote": "Ancillary OTC use; combination effects should not be assigned to Benadryl alone." }, { "slug": "melatonin", "medication": "Melatonin", "exposureState": "Known OTC/supplement regimen item", "exposureGrade": "E4", "effectEfficacyProvenance": "No material adverse-effect issue identified", "objectiveAnchor": "Regimen documentation", "providerConclusionResponse": "Supportive sleep agent", "conflictTension": "N/A", "openGap": "Minor", "frozenNote": "Do not inflate psychiatric prescription count", "publicationClassification": "OTC/supplement regimen item", "keyCanonicalEvidenceIds": ["EV-MED-0058"], "primarySourceIds": ["SRC-TR-D11"], "representativePinpoints": ["~02:08:41", "~02:09:23–02:10:10"], "readerNote": "Included as ancillary co-exposure, not a psychiatric-prescription count." }, { "slug": "cbd", "medication": "CBD", "exposureState": "Ancillary co-exposure reported", "exposureGrade": "E4", "effectEfficacyProvenance": "Relevant to Remeron efficacy report", "objectiveAnchor": "Contemporaneous report", "providerConclusionResponse": "No provider causal conclusion required", "conflictTension": "Confounds attribution to Remeron alone", "openGap": "Exact product/dose", "frozenNote": "Treat as ancillary exposure, not psychiatric prescription", "publicationClassification": "Ancillary co-exposure reported", "keyCanonicalEvidenceIds": ["EV-MED-0017"], "primarySourceIds": ["SRC-TR-D10"], "representativePinpoints": ["~04:36:46–04:36:56"], "readerNote": "Relevant because it confounds attribution of the Remeron efficacy report." }, { "slug": "aripiprazole-abilify", "medication": "Aripiprazole / Abilify", "exposureState": "Primary-record exposure not established", "exposureGrade": "E0", "effectEfficacyProvenance": "Appears in later consultant/litigation medication list", "objectiveAnchor": "No primary exposure anchor yet", "providerConclusionResponse": "N/A", "conflictTension": "Later list must not silently create exposure", "openGap": "GAP-MED-007", "frozenNote": "Do not count as established pre-event exposure", "publicationClassification": "Primary-record pre-event exposure not established", "keyCanonicalEvidenceIds": ["No positive primary exposure atom; GAP-MED-007 controls"], "primarySourceIds": ["Later medication-list evidence only"], "representativePinpoints": ["See validated Gap Register"], "readerNote": "Absence of a primary exposure anchor is preserved as E0, not converted into proof of non-use." }, { "slug": "bupropion-wellbutrin", "medication": "Bupropion / Wellbutrin", "exposureState": "Historical exposure reported; postpartum-period exposure not established", "exposureGrade": "Historical only", "effectEfficacyProvenance": "Reported effective and no side effects in historical intake", "objectiveAnchor": "Treating-provider testimony reviewing intake history", "providerConclusionResponse": "No 2022–Jan. 24 treatment course identified", "conflictTension": "Historical success cannot establish postpartum exposure", "openGap": "Exact historical duration/fill not material to MED-PRE", "frozenNote": "Keep historical-only; do not count in postpartum medication total", "publicationClassification": "Historical exposure reported; postpartum-period exposure not established", "keyCanonicalEvidenceIds": ["EV-MED-0065", "EV-MED-0067"], "primarySourceIds": ["SRC-TR-D10"], "representativePinpoints": ["~03:18:00–03:18:44", "Julie Paul ~04:16:05–04:16:16"], "readerNote": "Historical positive report is not a 2022–Jan. 24 exposure." }, { "slug": "propranolol", "medication": "Propranolol", "exposureState": "Historical trial reported; no meaningful 2022–Jan. 24 course established", "exposureGrade": "Historical only", "effectEfficacyProvenance": "Reported as one of medications she did well on in nursing school", "objectiveAnchor": "Treating-provider testimony reviewing historical history", "providerConclusionResponse": "No pre-event dose/fill/adherence course located", "conflictTension": "Day 19 occasional current use is post-event and must not backfill MED-PRE", "openGap": "Exact historical dose/duration", "frozenNote": "Historical-only family; post-event/current propranolol expressly excluded from MED-PRE", "publicationClassification": "Historical trial reported; no meaningful active pre-event course established", "keyCanonicalEvidenceIds": ["EV-MED-0068"], "primarySourceIds": ["SRC-TR-D10"], "representativePinpoints": ["Julie Paul ~04:16:05–04:16:16"], "readerNote": "Later/current use is post-event and excluded from MED-PRE." }, { "slug": "escitalopram-lexapro", "medication": "Escitalopram / Lexapro", "exposureState": "Collateral recollection only; primary pre-event exposure not established", "exposureGrade": "E0", "effectEfficacyProvenance": "Amy Bevins remembered an earlier medication discussed by Lindsay as Lexapro; no clean medication-specific efficacy/adverse-effect origin established", "objectiveAnchor": "No treating-provider/pharmacy/inventory anchor located", "providerConclusionResponse": "N/A", "conflictTension": "Later dark-thought disclosure was temporally separate in Bevins testimony and cannot be attributed to Lexapro", "openGap": "GAP-MED-010", "frozenNote": "Primary pre-event exposure not established", "publicationClassification": "Collateral recollection only; primary pre-event exposure not established", "keyCanonicalEvidenceIds": ["EV-MED-0069"], "primarySourceIds": ["SRC-TR-D8"], "representativePinpoints": ["~43:09–44:54"], "readerNote": "Medication-name recollection does not establish prescription, fill, ingestion, or causation." }, { "slug": "zolpidem-ambien", "medication": "Zolpidem / Ambien", "exposureState": "One-time Nov. 25 trial; later continuation proposal declined", "exposureGrade": "E3", "effectEfficacyProvenance": "No clean efficacy/adverse-effect result established from provider testimony reviewed", "objectiveAnchor": "Treating-provider testimony: Paul one-time dose; Jolotta knew ~5 mg had been tried", "providerConclusionResponse": "Jolotta considered 10 mg or controlled-release Ambien for middle-of-night wakeups; Lindsay was not receptive", "conflictTension": "One-time 5 mg trial must not be flattened into sustained medication exposure; later proposal is not ingestion", "openGap": "Exact ingestion/effect not independently measured", "frozenNote": "Later continuation proposal was declined", "publicationClassification": "One-time Nov. 25 trial; later continuation proposal declined", "keyCanonicalEvidenceIds": ["EV-MED-0070"], "primarySourceIds": ["SRC-TR-D10", "SRC-TR-D11"], "representativePinpoints": ["D10 ~04:28:50 onward", "D11 ~50:16–51:06"], "readerNote": "Later proposal is not a second exposure." }, { "slug": "olanzapine-zyprexa", "medication": "Olanzapine / Zyprexa", "exposureState": "Proposed in Dec. 2022; pre-event exposure not established; Day 21 says current/post-event use", "exposureGrade": "E0 pre-event", "effectEfficacyProvenance": "No pre-event efficacy/adverse-effect attribution established from Day 21", "objectiveAnchor": "No pre-event fill/admin/ingestion anchor in reconciled source; testimony says Seroquel + Valium were continued instead", "providerConclusionResponse": "Jolotta proposal was not selected in Dec.; later/current use belongs to post-event comparator", "conflictTension": "Medication-name presence could falsely inflate pre-event exposure count", "openGap": "None beyond final transcript wording check", "frozenNote": "Exclude current/post-event olanzapine use from MED-PRE", "publicationClassification": "Proposed Dec. 2022; pre-event exposure not established; later/current use post-event", "keyCanonicalEvidenceIds": ["EV-MED-0074"], "primarySourceIds": ["SRC-TR-D21-WHISPER"], "representativePinpoints": ["~42:57–44:20"], "readerNote": "Do not backfill later/current use into pre-event exposure." }, { "slug": "lithium", "medication": "Lithium", "exposureState": "Possible actual exposure referenced by Day 21 expert; temporal locus unresolved", "exposureGrade": "E0 for MED-PRE pending locus", "effectEfficacyProvenance": "No patient-specific pre-event effect/efficacy proposition can be assigned until date/facility is known", "objectiveAnchor": "No pre-event pharmacy/MAR anchor located in this passage", "providerConclusionResponse": "Day 21 expert appears to reference prior use, but Whisper loses where/when", "conflictTension": "1200 mg twice-daily lithium was a hypothetical toxicity example, not her dose", "openGap": "GAP-MED-011", "frozenNote": "Do not count lithium as MED-PRE exposure unless Rev/audio resolves the locus into the pre-event period", "publicationClassification": "Temporal locus unresolved; E0 for MED-PRE", "keyCanonicalEvidenceIds": ["EV-MED-0075", "EV-MED-0076"], "primarySourceIds": ["SRC-TR-D21-WHISPER"], "representativePinpoints": ["~45:11–45:55"], "readerNote": "1,200 mg twice daily was hypothetical, not a patient-specific dose." } ], "sourceMap": [ { "sourceId": "SRC-TR-D2", "title": "MA v. Lindsay Clancy Day 2 | Rev.pdf", "role": "Collateral firsthand testimony, including insomnia footprint", "authorityLimitation": "Primary trial testimony; retrospective as to pre-event observations", "publicUrl": "https://drive.google.com/file/d/1g5DmNx8385aMGQw2Xn8Q7qFoRocLgvzW/view", "sourceClass": "public archived trial transcript PDF", "higherAuthorityWorkingUrl": null, "higherAuthorityNote": null }, { "sourceId": "SRC-TR-D7", "title": "MA v. Lindsay Clancy Day 7 | Rev.pdf", "role": "Toxicology/laboratory testimony and interpretation", "authorityLimitation": "Primary laboratory testimony plus expert interpretation; timing limitations preserved", "publicUrl": "https://drive.google.com/file/d/1vrvcF8HzeXgJy58Qm69ajPjBVecfYEYk/view", "sourceClass": "public archived trial transcript PDF", "higherAuthorityWorkingUrl": null, "higherAuthorityNote": null }, { "sourceId": "SRC-TR-D8", "title": "MA v. Lindsay Clancy Day 8 | Rev.pdf", "role": "Collateral testimony and medication-history references", "authorityLimitation": "Primary trial testimony; collateral recollection is not primary exposure proof", "publicUrl": "https://drive.google.com/file/d/1OqmEIr2GsuzhAixlWMsjluBCZS9iSVAF/view", "sourceClass": "public archived trial transcript PDF", "higherAuthorityWorkingUrl": null, "higherAuthorityNote": null }, { "sourceId": "SRC-TR-D9", "title": "MA v. Lindsay Clancy Day 9 | Rev.pdf", "role": "Provider-observation/treatment evidence", "authorityLimitation": "Primary trial testimony; exact proposition/witness remains atom-specific", "publicUrl": "https://drive.google.com/file/d/1XZzM5VEpwIleiJuA7Fnu7pQ6O7BkxkEX/view", "sourceClass": "public archived trial transcript PDF", "higherAuthorityWorkingUrl": null, "higherAuthorityNote": null }, { "sourceId": "SRC-TR-D10", "title": "MA v. Lindsay Clancy Day 10 | Rev.pdf", "role": "Tufts, Julie Paul, provider history, pill-count and medication-event testimony", "authorityLimitation": "Primary trial testimony; underlying records/exhibits partly embedded", "publicUrl": "https://drive.google.com/file/d/1IWPP0GrdIAy_TE3gqSThltIX01zIIQAc/view", "sourceClass": "public archived trial transcript PDF", "higherAuthorityWorkingUrl": null, "higherAuthorityNote": null }, { "sourceId": "SRC-TR-D11", "title": "MA v. Lindsay Clancy Day 11 | Rev.pdf", "role": "Jolotta, MyChart, benzodiazepine/taper and medication chronology", "authorityLimitation": "Primary trial testimony quoting/reviewing contemporaneous records", "publicUrl": "https://drive.google.com/file/d/16le5zB31DuU2qyvQ7YjCbWz__U7swBv3/view", "sourceClass": "public archived trial transcript PDF", "higherAuthorityWorkingUrl": null, "higherAuthorityNote": null }, { "sourceId": "SRC-TR-D12", "title": "MA v. Lindsay Clancy Day 12 | Rev.pdf", "role": "Physical evidence / medication inventory chain", "authorityLimitation": "Primary evidence-handling testimony", "publicUrl": "https://drive.google.com/file/d/19IVIg1FuII3uYb4UDJ89BEgKzepeGqqD/view", "sourceClass": "public archived trial transcript PDF", "higherAuthorityWorkingUrl": null, "higherAuthorityNote": null }, { "sourceId": "SRC-TR-D13", "title": "MA v. Lindsay Clancy Day 13.pdf", "role": "Trial testimony used by one canonical medication atom", "authorityLimitation": "Primary trial testimony; proposition-level classification controls", "publicUrl": "https://drive.google.com/file/d/1dMlW9ZyeOy5eFvcvijBlajr8F7hCJKO3/view", "sourceClass": "public archived trial transcript PDF", "higherAuthorityWorkingUrl": null, "higherAuthorityNote": null }, { "sourceId": "SRC-TR-D20", "title": "MA v. Lindsay Clancy Day 20 | Rev.pdf", "role": "Retrospective expert interpretation and embedded review of clinical records", "authorityLimitation": "Expert testimony; underlying clinical records remain analytically distinct", "publicUrl": "https://drive.google.com/file/d/1V_46QGSZPJD225G2eg1ROekaUcdD8YrN/view", "sourceClass": "public archived Rev working transcript PDF used by sealed MED-PRE source state", "higherAuthorityWorkingUrl": "https://www.rev.com/transcripts/ma-v-lindsay-clancy-day-20", "higherAuthorityNote": "Rev's direct working-transcript page is public and dated August 26, 2026." }, { "sourceId": "SRC-TR-D21-WHISPER", "title": "MA v Lindsay Clancy Day 21 (Whisper CLI)", "role": "Provisional Day 21 reconciliation and false-positive controls", "authorityLimitation": "Local transcription; not Rev-equivalent; transcript-sensitive wording remains qualified", "publicUrl": "https://docs.google.com/document/d/1QKROXTJj2dVWa46CtCPA6d5_rKetQY9BGYKlGpO7sDQ/edit", "sourceClass": "publicly readable archived local Whisper CLI transcription used by sealed MED-PRE source state", "higherAuthorityWorkingUrl": "https://www.rev.com/transcripts/ma-v-lindsay-clancy-day-21", "higherAuthorityNote": "A Rev Day 21 working transcript became publicly available on August 27, 2026 after the earlier provenance check. The sealed v1.1 classifications do not silently substitute the newer transcript for the source that was actually audited." }, { "sourceId": "SRC-TR-OPEN", "title": "MA v. Lindsay Clancy Opening Statements | Rev.pdf", "role": "Mixed same-day source: opening argument plus later timestamped witness testimony; EV-MED-0031/0033 rely on the later Patrick Clancy testimony segment, not counsel's opening argument.", "authorityLimitation": "MIXED SOURCE — opening statements are not evidence; later witness testimony is evidentiary when specifically timestamped and atom-classified.", "publicUrl": "https://drive.google.com/file/d/1YIDb3sPCUTt3ubNtWLEvI0f5N1XzdwzB/view", "sourceClass": "public archived mixed trial-day transcript PDF", "higherAuthorityWorkingUrl": null, "higherAuthorityNote": null } ], "limitations": [ "This audit is limited to the evidentiary corpus presently available and reviewed for MED-PRE v1.1.", "Trial testimony may summarize underlying records that are not independently reproduced in full.", "Toxicology attribution can be limited by exact medication-administration and specimen timing.", "Pill counts constrain but do not prove ingestion.", "The sealed v1.1 audit used a local Day 21 Whisper CLI transcription conservatively; a Rev Day 21 working transcript became available on August 27 and is recorded for later versioned reconciliation rather than silently substituted into the sealed source state.", "New primary evidence may change a bounded field and must trigger a versioned amendment rather than a silent overwrite." ], "openQuestions": [ "Exact January 16 diazepam 2 mg quantity/SIG.", "South Shore emergency medication-administration timing relative to toxicology draw.", "Exact 2022 Prozac quantity/duration.", "Exact Buspar/hydroxyzine dose chronology.", "Exact day-by-day Seroquel dosing.", "Underlying Apple Watch/Health data for reported heart-rate fluctuation.", "Primary-record exposure, if any, to Abilify or Lexapro.", "Remaining prescription-date versus fill-date distinctions.", "Final Rev/audio reconciliation of the Day 21 Lamictal wording.", "Temporal locus of the Day 21 lithium reference." ], "versionHistory": [ { "version": "1.0", "date": "2026-08-27", "status": "historical frozen source-state", "note": "Preserved the source state before Day 21 reconciliation and final validation closure." }, { "version": "1.1", "date": "2026-08-27", "status": "validated / sealed for publication", "note": "Final validated source-state authorized for architectural publication build after independent validation, clause-level traceability, editorial QC, citation-map normalization, and source-map QC." } ], "corrections": [] }